Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00996918) was an extension study involving people with Alzheimer's disease who had previously taken part in an earlier trial of a drug called bapineuzumab. A total of 202 participants were enrolled across five groups, depending on what dose they had received previously and what dose they were assigned to in this extension phase. The trial's primary focus was on counting how many participants experienced a serious unwanted medical event (called a serious adverse event). Secondary measures looked at changes in thinking and memory abilities, day-to-day functioning, and behavioural symptoms over time, using standardised rating scales. Notably, the reported data shows that none of the 202 participants completed the study — all were recorded as "not completed." The reported data shows that serious adverse events were recorded in 6 out of 39 participants in the placebo-then-0.5 mg/kg group, 10 out of 66 in the continuous 0.5 mg/kg group, 1 out of 37 in the placebo-then-1.0 mg/kg group, 11 out of 56 in the continuous 1.0 mg/kg group, and 0 out of 4 in the 2.0 mg/kg-then-1.0 mg/kg group. For the secondary measures, the cognitive scale (scored 0–70, where higher means more impairment) showed scores generally increasing over time across all groups, meaning participants' recorded impairment grew over the course of the study. Similarly, the daily functioning scale (scored out of 100, where higher is better) showed declining scores across all groups over time. Behavioural symptom scores also generally increased over time in most groups. The reported data for the smallest group (4 participants in the 2.0 mg/kg-then-1.0 mg/kg group) was not reported for the secondary outcome measures. It is worth noting that because no participants completed the study, the results should be interpreted with that important limitation in mind — the data was not reported in a way that explains why. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 27334799) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Alzheimer's Disease Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must have already completed a specific earlier study called "3133K1-3000" and had a brain scan (MRI) that confirmed a diagnosis of Alzheimer's disease
- You must score 10 or higher on a standard memory and thinking test called the Mini-Mental Status Examination (MMSE) at the screening appointment
- You must have a caregiver who is able to come with you to all clinic visits throughout the trial
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You may not be eligible if you have any health or mental health condition, or any significant abnormal test result, that the study doctor believes would make it unsafe for you to participate or make it hard to measure how you respond to the treatment
- You may not be eligible if your brain MRI scan shows any significant unusual findings or abnormalities
- You may not be eligible if you have taken any experimental drugs or used any experimental medical devices (other than the drug bapineuzumab, which is being studied in this trial) in the 60 days before your screening appointment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 5 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Participants Reporting a Serious Adverse Event.
Other options
Data last synced from ClinicalTrials.gov: 6 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.